ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years
Darren Cowzer
Matched on ORCID iD 0000-0002-0969-3259; OpenAlex author ID A5005311716. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers
Papers 4
- Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
- Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf139↗
- Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. Co-author DOI 10.1093/jnci/djae095↗
- Targeting KRAS in Pancreatic Cancer. Co-author DOI 10.3390/jpm12111870↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marinela Capanu · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Anna M. Varghese · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Fergus Keane · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Wungki Park · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Eileen Mary O'Reilly · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Anupriya Singhal · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Fiyinfolu O. Balogun · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Kenneth H. Yu · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Fionnuala Crowley · 2 shared papers, 2025 · strength 0.36
- Alice Chia-Chi Wei · 2 shared papers, 2025 · strength 0.36
- Austin G. Duffy · 1 shared paper, 2022 · strength 0.20
- Lily V. Saadat · 1 shared paper, 2025 · strength 0.19
- Rona D. Yaeger · 1 shared paper, 2024 · strength 0.17
- Vinod P. Balachandran · 1 shared paper, 2025 · strength 0.17
- Kevin C. Soares · 1 shared paper, 2025 · strength 0.17
- Ghassan K. Abou‐Alfa · 1 shared paper, 2025 · strength 0.17
- T. Peter Kingham · 1 shared paper, 2025 · strength 0.17
- Michael Ian D'Angelica · 1 shared paper, 2025 · strength 0.17
- Jeffrey A. Drebin · 1 shared paper, 2025 · strength 0.17
- David Paul Kelsen · 1 shared paper, 2025 · strength 0.17
- William R. Jarnagin · 1 shared paper, 2025 · strength 0.17
- Christopher H. Crane · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.